Keyphrases
Glioblastoma
84%
High-grade Glioma
54%
Tumor
52%
Bevacizumab
41%
Newly Diagnosed Glioblastoma
38%
Radiation Therapy
35%
Temozolomide
34%
Brain Tumor
31%
Glioblastoma multiforme
29%
Primary Brain Tumor
26%
Overall Survival
25%
Dynamic Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)
24%
Radiotherapy
24%
NRG Oncology
22%
Dynamic Contrast-enhanced
19%
Radiation Therapy Oncology Group
19%
Chemotherapy
18%
Glioma
18%
Tumor Treating Fields
17%
Progression-free Survival
16%
Recurrent Glioblastoma
16%
Phase II Study
14%
Recursive Partitioning Analysis
14%
Hazard Ratio
14%
Magnetic Resonance Imaging
14%
Southwest Oncology Group
13%
Surgical Resection
12%
Brain Metastases
12%
Oncology
12%
Immune Checkpoint Inhibitors
11%
Vasogenic Edema
11%
Neuro-oncology
10%
Phase II Trial
10%
Anaplastic Astrocytoma
10%
Cisplatin
10%
Newly Diagnosed
10%
Treatment Change
10%
Malignant Glioma
9%
Failed Repair
9%
Low-grade Glioma
9%
Patient Survival
9%
Confidence Interval
9%
Tumor Progression
9%
Methylation Status
9%
Adult Patients
9%
Partial Response
9%
Retrospective Analysis
8%
Carmustine
8%
Central Nervous System Tumors
8%
Pembrolizumab
8%
Medicine and Dentistry
Glioblastoma
100%
Neoplasm
66%
Ganglioglioma
61%
Radiation Therapy
44%
Oncology
38%
Brain Tumor
33%
Temozolomide
33%
Magnetic Resonance Imaging
29%
Overall Survival
29%
Bevacizumab
28%
Malignant Neoplasm
28%
Surgery
27%
Progression Free Survival
21%
Disease
18%
Neuro-Oncology
14%
Brain Metastasis
14%
Meningioma
13%
Metastatic Carcinoma
12%
Treatment Response
11%
Central Nervous System Tumor
11%
Clinical Trial
11%
Immunotherapy
10%
Cisplatin
10%
Neurologic Disease
10%
Methylation
10%
Recurrent Disease
9%
Oligoastrocytoma
9%
DNA Mismatch Repair
9%
Hazard Ratio
9%
Group Trial
9%
Immune Checkpoint Inhibitor
9%
Nivolumab
8%
Medulloblastoma
8%
Encephalitis
8%
Pembrolizumab
8%
Tumor Treating Fields
8%
Oligodendroglioma
8%
Carmustine
8%
Arm
8%
Recursive Partitioning
8%
External Beam Radiotherapy
8%
Brain Cancer
7%
Neurological Complication
7%
T Cell
7%
Tumor Progression
7%
Symptom
7%
Re-Irradiation
6%
Magnetic Resonance Imaging
6%
Diagnosis
6%
Survival Rate
6%